

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/749,144
				Filing Date	12/29/2003
				First Named Inventor	Daniel M. GORMAN
				Art Unit	1646
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	DX01170K1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/DJ/	AX	US - 6,150,502	11-21-2000	STRACHAN	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/DJ/	AY	KOSKINEN, et al., <i>J. Immunol.</i> 160:4943-50. (1998) "The structure of avian CD5 implies a conserved function"	

Examiner Signature	/Dong Jiang/	Date Considered	05/13/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-768-9199) and select option 2.



PTO/SB/08 (MODIFIED)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Sheet	1	of	1	Application Number	10/749,144
				Filing Date	12/29/2003
				First Named Inventor	Daniel M. GORMAN
				Art Unit	1646
				Examiner Name	
				Attorney Docket Number	DX01170K1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/DJ/	AZ	WO 01/90358 A	11-29-2001	Schering Corporation		
/DJ/	BA	WO 03/006609 A	01-23-2003	Zymogenetics, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/DJ/	BB	GORMAN (2002) EBI accession no. GSN:AAU11356 "Human DNAX cytokine receptor subunit 9 (DCRS9) polypeptide"	
/DJ/	BC	KUESTNER et al. (2003) EBI accession no. GSN:ABP71261 "Human Zcytor21-g13 polypeptide"	

Examiner Signature	/Dong Jiang/	Date Considered	05/13/2007
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/749,144
				Filing Date	Herewith
				First Named Inventor	Daniel M. GORMAN
				Art Unit	1646
				Examiner Name	D. Jiang
				Attorney Docket Number	DX01170K1
Sheet	1	of	3		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear	T ^o
		Country Code ² Number ⁴ Kind Code ⁵ (if known)				
/DJ/	AA	WO 96/29408	09-26-1996	YAO, et al.		
↓	AB	WO 99/55865	11-04-1999	STRACHAN, et al.		
	AC	WO 01/46420	06-28-2001	CHEN, et al.		
	AD	WO 01/68859	09-20-2001	S. JING		
	AE	WO 03/006609	01-23-2003	KUESTNER, et al	Pages 8 and 84.	

Examiner Signature	/Dong Jiang/	Date Considered	05/13/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number		
			Filing Date	Herewith	
			First Named Inventor	Daniel M. GORMAN	
			Art Unit		
			Examiner Name		
Sheet	2	of	3	Attorney Docket Number	DX01170K1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/DJ/	AF	J. FERNANDO BAZAN, et al., Nature, 379:591, February 15, 1996. "A newly defined interleukin-1?"	
	AG	H. BLOECKER, et al., EMBL Database, Accession Number AL133097, November 17, 1999. Definition: Homo sapiens mRNA; cDNA DKFZp434N1928 (from clone DKFZp434N1928)	
	AH	GenBank. LOCUS NM_013278, 1048 bp, mRNA linear, PRI 04-OCT-2003 DEFINITION Homo sapiens interleukin 17C (IL17C), mRNA.	
	AI	THOMAS J. GONDA and RICHARD J. D'ANDREA, Blood, 89(2):355-369, January 15, 1997. "Activating Mutations in Cytokine Receptors: Implications for Receptor Function and Role in Disease."	
	AJ	D. HAUDENSCHILD, et al., J. Biol. Chem. 277(6):4309-4316, Published JBC Papers in Press, November 12, 2001. "Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer."	
	AK	S. HURST, et al., J. Immunol. 169:443-453, July 2002. "New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25."	
	AL	J. LEE, et al., J. Biol. Chem. 276(2):1660-1664, Published JBC Papers in Press October 31, 2000. "IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1."	
	AM	ALEXANDER LEVITSKI, Current Opinion in Cell Biology, 8:239-244, 1996. "Targeting signal transduction for disease therapy"	
	AN	H. LI, et al., Proc. Natl. Acad. Sci. USA, 97(2):773-778, January 18, 2000. "Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family."	
	AO	C. LOCK, et al., Nature Medicine, 8(5):500-508, May 2002. "Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis."	
	AP	M. MARRA, et al., EMBL Database, Accession Number AW107583, October 21, 1999. Definition: u191g04.y1 Sugano mouse kidney mkiia Mus musculus cDNA clone IMAGE:2159478 5', mRNA sequence	
	AQ	T.A. MOSELEY, et al., Cytokine and Growth Factor Reviews 14:155-174, 2003. "Interleukin-17 family and IL-17 receptors."	
	AR	NCI-CGAP, EMBL Database, Accession Number A1861981, July 22, 1999. Definition: ty30c03.x1 NCI_CGAP_Ut2 Homo sapiens cDNA clone IMAGE:2280580 3', mRNA sequence	
	AS	DAVID H. PRESKY, et al., Proc. Natl. Acad. Sci. USA, 93:14002-14007, November 1996. "A functional interleukin 12 receptor complex is composed of two b-type cytokine receptor subunits"	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	Herewith
				First Named Inventor	Daniel M. GORMAN
				Art Unit	
				Examiner Name	
				Attorney Docket Number	DX01170K1
Sheet	3	of	3		

[illegible]

Examiner Signature	/Dong Jiang/	Date Considered	05/13/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.